Clinical Trials Browser

Breast Neoplasms

Osteosarcoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Lymphoma, T-Cell, Cutaneous

Lymphoma, T-Cell, Peripheral

Colorectal Neoplasms

Recurrence, Leukemia, Myeloid, Acute

HR Positive HER2 Negative Advanced Breast Cancer

Esophageal Squamous Cell Carcinoma

Breast Neoplasms

Breast Neoplasms

HR+/HER2- Breast Cancer

Carcinoma, Non-Small-Cell Lung

Lymphoma, T-Cell, Peripheral

Triple Negative Breast Neoplasms

Breast Neoplasms

HR+/HER2- Advanced Breast Cancer

Breast Neoplasms

Recurrence, Lymphoma, T-Cell, Peripheral

Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Leukemia, Leukemia, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Neoplasm Metastasis, Triple Negative Breast Neoplasms

Breast Neoplasms

Leukemia, Myeloid, Acute

Lymphoma, T-Cell, Peripheral

Lymphoma, Non-Hodgkin

Breast Neoplasms

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Advanced Breast Cancer

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

Breast Neoplasms

Esophageal Squamous Cell Carcinoma

Recurrence, Lymphoma, B-Cell

Lymphoma, T-Cell, Peripheral

Lymphoma, Large B-Cell, Diffuse

Triple Negative Breast Neoplasms

Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden

Lymphoma, Large B-Cell, Diffuse

Hodgkin Disease

Lymphoma, T-Cell, Peripheral

Recurrence, Lymphoma, T-Cell, Peripheral

Recurrence, Lymphoma, Large B-Cell, Diffuse

Lymphoma, T-Cell, Cutaneous

Neoplasms, Experimental

Lymphoma, Large B-Cell, Diffuse

Neoplasms, Experimental

Multiple Myeloma

Clinical Trials

CINDERELLA

Chidamide Combined With Toripalimab in Sarcoma

Tucidinostat Plus Apatinib for Advanced Osteosarcoma

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

TRUMP

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC

Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia

Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor

Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer

Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Biomarker Guided Treatment in DLBCL

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

DLBCL

Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM